AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21075465 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy for heart failure
Number of subjects: 577
Study 20397457 — intervention group
Group type: EXPERIMENTAL
Intervention: Body acupuncture plus auricular‐plaster therapy
Number of subjects: 90
Study 20397457 — intervention group
Group type: COMPARATOR
Intervention: Control group (Baihui (GV 20)‐through‐Sishencong (EX‐HN1) puncture, auricular‐plaster therapy and moxibustion on the back‐shu points not used)
Number of subjects: 90
Study 17666604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 1 g once daily for 5 days
Number of subjects: 235
Study 17666604 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 2 g once daily for 2 days
Number of subjects: 235
Study 17666604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235
Study 15644654 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway pressure signal (Paw) added to pressure tracings
Number of subjects: 121
Study 15644654 — intervention group
Group type: COMPARATOR
Intervention: No airway pressure signal (Paw)
Number of subjects: 121
Study 12244386 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/Kg chlorpromazine intravenously
Number of subjects: 30
Study 12244386 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 ml of saline intravenous injections)
Number of subjects: 30
Study 9988395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen (E2 valerate, 2 mg/d) plus medroxyprogesterone acetate (5 mg/d) administered during weeks 3, 4, 7, and 8 for 8 weeks
Number of subjects: 36
Study 9988395 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50‐microg or 100‐microg E2 patch)
Number of subjects: 36
Study 9988395 — intervention group
Group type: COMPARATOR
Intervention: Control group (Seventeen premenopausal women)
Number of subjects: 36
Study 7564363 — intervention group
Group type: EXPERIMENTAL
Intervention: Remikiren (single oral administration)
Number of subjects: 16
Study 2197005 — intervention group
Group type: COMPARATOR
Intervention: 5% lidocaine 0.5 mg.kg‐1 in 7.5% glucose (n = 20)
Number of subjects: 42
Study 2197005 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% meperidine 0.5 mg.kg‐1 (n = 22)
Number of subjects: 42
Study 6448650 — intervention group
Group type: EXPERIMENTAL
Intervention: zimelidine
Number of subjects: 24
Study 6448650 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 30991945 — intervention group
Group type: EXPERIMENTAL
Intervention: Confusion Assessment Method (CAM) assessment training
Number of subjects: 37
Study 30991945 — intervention group
Group type: EXPERIMENTAL
Intervention: CAM assessments conducted by trained research assistants
Number of subjects: 37
Study 28821260 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI (glycopyrrolate/formoterol fumarate 18/9.6 μg) administered twice daily
Number of subjects: 110
Study 28821260 — intervention group
Group type: EXPERIMENTAL
Intervention: GFF MDI
Number of subjects: 110
Study 28821260 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 110
Study 28821260 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 110
Study 26122460 — intervention group
Group type: EXPERIMENTAL
Intervention: PACES intervention (8-week group sessions co-led by a psychologist and trained peer with epilepsy)
Number of subjects: 83
Study 26122460 — intervention group
Group type: EXPERIMENTAL
Intervention: PACES intervention
Number of subjects: 83
Study 26122460 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (control group)
Number of subjects: 83
Study 24499425 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care acupressure
Number of subjects: 220
Study 24499425 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 220
Study 20922438 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 323
Study 20922438 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 323
Study 19074663 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous highly active antiretroviral therapy (HAART) for 24 months (arm A)
Number of subjects: 58
Study 19074663 — intervention group
Group type: COMPARATOR
Intervention: Intermittent highly active antiretroviral therapy (HAART) for 24 months (arm B)
Number of subjects: 58
Study 16705107 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/d
Number of subjects: 143
Study 16705107 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 20 mg/d
Number of subjects: 143
Study 16705107 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 40 mg/d
Number of subjects: 143
Study 16705107 — intervention group
Group type: EXPERIMENTAL
Intervention: Policosanol 80 mg/d
Number of subjects: 143
Study 16705107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 12125326 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based practice in dentistry
Number of subjects: 0
Study 10071280 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation radiotherapy (RT)
Number of subjects: 100
Study 10071280 — intervention group
Group type: COMPARATOR
Intervention: No consolidation radiotherapy (RT)
Number of subjects: 100
Study 7545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (5 g total)
Number of subjects: 75
Study 7545448 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibitory units total)
Number of subjects: 75
Study 7545448 — intervention group
Group type: COMPARATOR
Intervention: Control (neither drug nor placebo)
Number of subjects: 75
Study 2341581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 121
Study 2341581 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 90 mg
Number of subjects: 121
Study 2341581 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 121
Study 7000136 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral psoralen and long-wave ultraviolet light (treated side)
Number of subjects: 22
Study 7000136 — intervention group
Group type: COMPARATOR
Intervention: Topical psoralen and long-wave ultraviolet light (previously control side)
Number of subjects: 22
Study 31783132 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicy stimulation
Number of subjects: 160
Study 31783132 — intervention group
Group type: EXPERIMENTAL
Intervention: Spicy food consumption ≥3 days/week
Number of subjects: 160
Study 31783132 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 160
Study 31783132 — intervention group
Group type: COMPARATOR
Intervention: Sweet stimulation
Number of subjects: 160
Study 31783132 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term spicy diet
Number of subjects: 160
Study 29361199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavrilimumab 100 mg every other week plus methotrexate
Number of subjects: 442
Study 29361199 — intervention group
Group type: COMPARATOR
Intervention: Mavrilimumab (30, 100, or 150 mg) or placebo every other week plus methotrexate
Number of subjects: 442
Study 28456025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 75
Study 28456025 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 75
Study 26297124 — intervention group
Group type: EXPERIMENTAL
Intervention: Di-Huang-Yi-Zhi (DHYZ) with donepezil
Number of subjects: 60
Study 26297124 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (5 mg for 1 month, then 10 mg for the rest of the months, once daily)
Number of subjects: 60
Study 22751028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin + Dexamethasone
Number of subjects: 108
Study 22751028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 108
Study 22751028 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 108
Study 21050887 — intervention group
Group type: EXPERIMENTAL
Intervention: DMB‐SR floating tablets (HPMC K4M 25 mg, sodium bicarbonate 20 mg, hexadecanol 18 mg)
Number of subjects: 0
Study 21050887 — intervention group
Group type: COMPARATOR
Intervention: Conventional DMB‐SR tablets
Number of subjects: 0
Study 18316794 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 693
Study 18316794 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 693
Study 16315025 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen + 2.5 mg medroxyprogesterone acetate (CEE/MPA)
Number of subjects: 246
Study 16315025 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg 17beta estradiol + 0.5 mg norethindrone acetate (E2/NETA)
Number of subjects: 246
Study 14570797 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bolus of propofol
Number of subjects: 75
Study 14570797 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of propofol
Number of subjects: 75
Study 14570797 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus followed by infusion of propofol
Number of subjects: 75
Study 10195538 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 4 microg/mL (Group R4F)
Number of subjects: 244
Study 10195538 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL alone (Group R)
Number of subjects: 244
Study 10195538 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 1 microg/mL (Group R1F)
Number of subjects: 244
Study 10195538 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl 2 microg/mL (Group R2F)
Number of subjects: 244
Study 10195538 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 244
Study 10195538 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 2 mg/mL with fentanyl (all doses)
Number of subjects: 244
Study 7756100 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine transdermal system (PTS)
Number of subjects: 6
Study 7756100 — intervention group
Group type: COMPARATOR
Intervention: Oral solution
Number of subjects: 6
Study 7756100 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion
Number of subjects: 6
Study 2179137 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus sulbactam
Number of subjects: 83
Study 2179137 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 83
Study 231299 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg cephradine every 6 h for 7 days
Number of subjects: 98
Study 231299 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg pivmecillinam every 6 h for 7 days
Number of subjects: 98
Study 231299 — intervention group
Group type: COMPARATOR
Intervention: 500 mg cephradine
Number of subjects: 98
Study 231299 — intervention group
Group type: COMPARATOR
Intervention: 400 mg pivmecillinam
Number of subjects: 98
Study 30040135 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, single oral dose)
Number of subjects: 40
Study 30040135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30040135 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intravenous amisulpride
Number of subjects: 40
Study 30040135 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous amisulpride
Number of subjects: 40
Study 28638011 — intervention group
Group type: COMPARATOR
Intervention: Group I (patients without ventral hernias)
Number of subjects: 141
Study 28638011 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (patients with ventral hernias)
Number of subjects: 141
Study 28638011 — intervention group
Group type: COMPARATOR
Intervention: Subgroup AI (primary operation)
Number of subjects: 141
Study 28638011 — intervention group
Group type: COMPARATOR
Intervention: Subgroup BI (re-operation)
Number of subjects: 141
Study 27900198 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker-sole shoes
Number of subjects: 20
Study 27900198 — intervention group
Group type: COMPARATOR
Intervention: Flat-sole shoes
Number of subjects: 20
Study 24694924 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic oxytocin (24 IU)
Number of subjects: 40
Study 24694924 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 40
Study 22113087 — intervention group
Group type: EXPERIMENTAL
Intervention: Org 25935 (glycine transporter-1 inhibitor)
Number of subjects: 12
Study 22113087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 19189246 — intervention group
Group type: EXPERIMENTAL
Intervention: S. chrysotrichum herbal medicinal product (Sc-hmp), standardized in 1.89 mg of SC-2, administered as vaginal suppositories daily for 7 nights
Number of subjects: 101
Study 19189246 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole (400 mg), administered as vaginal suppositories daily for 7 nights
Number of subjects: 101
Study 17209694 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched distraction trial for low monitors
Number of subjects: 178
Study 17209694 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched sensation monitoring trial for high monitors
Number of subjects: 178
Study 17209694 — intervention group
Group type: COMPARATOR
Intervention: Mismatched sensation monitoring trial for low monitors
Number of subjects: 178
Study 17209694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain tolerance scores
Number of subjects: 178
Study 17209694 — intervention group
Group type: COMPARATOR
Intervention: Pain intensity
Number of subjects: 178
Study 17209694 — intervention group
Group type: COMPARATOR
Intervention: Pain affect
Number of subjects: 178
Study 17209694 — intervention group
Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 178
Study 16215875 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified curriculum intervention schools
Number of subjects: 508
Study 11991625 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g lactulose meal
Number of subjects: 8
Study 11991625 — intervention group
Group type: COMPARATOR
Intervention: 40 g sucrose meal followed by colonic infusion of 40 g lactulose
Number of subjects: 8
Study 9704778 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B6 supplementation
Number of subjects: 37
Study 9704778 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B6 supplementation with aspirin
Number of subjects: 37
Study 9704778 — intervention group
Group type: COMPARATOR
Intervention: Previous pregnancies (control group)
Number of subjects: 37
Study 8556974 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (2 mg QD)
Number of subjects: 43
Study 8556974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 31714583 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (300/150 μg)
Number of subjects: 12
Study 31714583 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 12
Study 29596222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (MCA) 10 mg/kg/d for ≥21 days
Number of subjects: 30
Study 29596222 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B Deoxycholate (AmB-D) 1 mg/kg/d for ≥21 days
Number of subjects: 30
Study 29596222 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (MCA)
Number of subjects: 30
Study 29596222 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B Deoxycholate (AmB-D)
Number of subjects: 30
Study 28723799 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE with Huaier granule
Number of subjects: 62
Study 28723799 — intervention group
Group type: COMPARATOR
Intervention: TACE with GSPs plus lobaplatin chemotherapy
Number of subjects: 62
Study 25028065 — intervention group
Group type: EXPERIMENTAL
Intervention: Encenicline (alpha-7 nicotine agonist)
Number of subjects: 319
Study 25028065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 319
Study 23319176 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of HZ vaccine (0.65 mL)
Number of subjects: 759
Study 23319176 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HZ vaccine at 0 and 1 month
Number of subjects: 759
Study 23319176 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of HZ vaccine at 0 and 3 months
Number of subjects: 759
Study 23319176 — intervention group
Group type: COMPARATOR
Intervention: Two-dose vaccination (both schedules)
Number of subjects: 759
Study 23319176 — intervention group
Group type: EXPERIMENTAL
Intervention: All three vaccination schedules
Number of subjects: 759
Study 23319176 — intervention group
Group type: EXPERIMENTAL
Intervention: HZ vaccine
Number of subjects: 759
Study 22018642 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg for 6 months
Number of subjects: 66
Study 22018642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 19253247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 135
Study 19253247 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 135
Study 19253247 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 135
Study 16717170 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP testing (n = 225)
Number of subjects: 452
Study 16717170 — intervention group
Group type: COMPARATOR
Intervention: Standard assessment (n = 227)
Number of subjects: 452
Study 15571954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraventricular chemotherapy (IT)
Number of subjects: 35
Study 15571954 — intervention group
Group type: COMPARATOR
Intervention: Non-intrathecal treatment (non-IT)
Number of subjects: 35
Study 11768138 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects labeled with novel nouns
Number of subjects: 144
Study 11768138 — intervention group
Group type: EXPERIMENTAL
Intervention: Objects labeled with familiar nouns
Number of subjects: 144
Study 11768138 — intervention group
Group type: COMPARATOR
Intervention: Objects not labeled
Number of subjects: 144
Study 9415525 — intervention group
Group type: EXPERIMENTAL
Intervention: Deodorant catamenial pads
Number of subjects: 190
Study 9415525 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-deodorant catamenial pads
Number of subjects: 190
Study 9415525 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 190
Study 8106654 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 40 mg)
Number of subjects: 106
Study 8106654 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 to 60 mg)
Number of subjects: 106
Study 2446057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg b.i.d.)
Number of subjects: 119
Study 2446057 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa (250-500 mg b.i.d.)
Number of subjects: 119
Study 2446057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 119
Study 2446057 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 119
Study 30400774 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical activity intervention consisting of 16 weeks structured exercise, physical activity self‐monitoring and motivational coaching.
Number of subjects: 200
Study 30400774 — intervention group
Group type: COMPARATOR
Intervention: Usual care/minimal intervention (Control group).
Number of subjects: 200
Study 27571100 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten Contamination Elimination Diet (GCED) for 3 months (Cohort A)
Number of subjects: 29
Study 27571100 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gluten-free diet (GFD) for a minimum of 2 years (Cohort B)
Number of subjects: 29
Study 27571100 — intervention group
Group type: COMPARATOR
Intervention: Early control (baseline after 12-18 months of GFD)
Number of subjects: 29
Study 24060164 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoAdhesive mesh (AA)
Number of subjects: 90
Study 24060164 — intervention group
Group type: COMPARATOR
Intervention: Classic Lichtenstein technique with sutured polypropylene mesh (CL)
Number of subjects: 90
Study 22956167 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-filled pen (PFP)
Number of subjects: 640
Study 22956167 — intervention group
Group type: COMPARATOR
Intervention: Pre-filled syringe (PFS)
Number of subjects: 640
Study 20569086 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day
Number of subjects: 254
Study 20569086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 18520294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (monotherapy)
Number of subjects: 0
Study 18520294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (in combination with chemotherapy)
Number of subjects: 0
Study 18520294 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (in combination with epidermal growth factor receptor inhibitors)
Number of subjects: 0
Study 18520294 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (in combination with cytotoxic chemotherapy)
Number of subjects: 0
Study 15893182 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg and fenofibrate 200 mg
Number of subjects: 56
Study 15893182 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate 200 mg
Number of subjects: 56
Study 12887139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine 150 mg/kg
Number of subjects: 76
Study 12887139 — intervention group
Group type: EXPERIMENTAL
Intervention: D-amphetamine 20 mg
Number of subjects: 76
Study 12887139 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 37.5 mg
Number of subjects: 76
Study 12887139 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 300 mg/70 kg
Number of subjects: 76
Study 12887139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 10505365 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (evaluated and treated by telemedicine nurse and rural emergency physician via telemedicine link)
Number of subjects: 104
Study 10505365 — intervention group
Group type: COMPARATOR
Intervention: Control group (diagnosed and treated by suburban emergency physician)
Number of subjects: 104
Study 10505365 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 104
Study 10505365 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 8636359 — intervention group
Group type: COMPARATOR
Intervention: Bread (approximately 85 kcal)
Number of subjects: 6